HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review.

IF 1.9 4区 医学 Q4 IMMUNOLOGY
Jos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, Manuel Vélez-Díaz-Pallarés, Antonio Castro, Darío Rubio-Rodríguez, Carlos Rubio-Terrés
{"title":"HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review.","authors":"Jos柩 L Blanco-Arévalo, Miguel García-Deltoro, Miguel Torralba, Manuel Vélez-Díaz-Pallarés, Antonio Castro, Darío Rubio-Rodríguez, Carlos Rubio-Terrés","doi":"10.24875/AIDSRev.24000011","DOIUrl":null,"url":null,"abstract":"<p><p>We describe and analyze resistance-associated mutations (RM) and virological failures (VF) on antiretroviral therapy using the latest approved integrase inhibitors (INIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB), together with their companion drugs in fixed-dose formulations: BIC/emtricitabine/tenofovir; CAB/rilpivirine; DTG/abacavir/lamivudine; DTG/emtricitabine/tenofovir; and DTG/lamivudine. Systematic literature searches were conducted in PubMed and other electronic databases for clinical studies published between January 2010 and May 2023, according to preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA), which analyzed VFs and RMs of INIs. Fifty clinical studies were included in the synthesis. VF in antiretroviral treatment (ART)-naïve patients occurred in 0.7-4.0%, 0.6-1.4%, and 0.6-9.0% of patients treated with DTG, BIC, and CAB, respectively. VF was reported in patients with previous ART in 0-8.1%, 0-2.0%, and 0.4-2.3% of those treated with DTG, BIC, and CAB, respectively. RMs were detected in ART-naïve patients in only one study with DTG (0.3%), none of the studies with BIC, and three of the studies with CAB (0.1-5.4%). In ART-experienced patients, RMs were detected in 0-1.9% of DTG-treated patients. No cases of RM were detected in the 11 BIC studies reviewed. In the case of CAB, RMs were detected in eight studies, ranging from 0.3% to 1.9% of patients. In conclusion, RM rates in the studies reviewed were generally low using the latest INIs. This review identified BIC as the INI with the lowest number of observed VF and lack of RM.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 2","pages":"67-79"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/AIDSRev.24000011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We describe and analyze resistance-associated mutations (RM) and virological failures (VF) on antiretroviral therapy using the latest approved integrase inhibitors (INIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB), together with their companion drugs in fixed-dose formulations: BIC/emtricitabine/tenofovir; CAB/rilpivirine; DTG/abacavir/lamivudine; DTG/emtricitabine/tenofovir; and DTG/lamivudine. Systematic literature searches were conducted in PubMed and other electronic databases for clinical studies published between January 2010 and May 2023, according to preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA), which analyzed VFs and RMs of INIs. Fifty clinical studies were included in the synthesis. VF in antiretroviral treatment (ART)-naïve patients occurred in 0.7-4.0%, 0.6-1.4%, and 0.6-9.0% of patients treated with DTG, BIC, and CAB, respectively. VF was reported in patients with previous ART in 0-8.1%, 0-2.0%, and 0.4-2.3% of those treated with DTG, BIC, and CAB, respectively. RMs were detected in ART-naïve patients in only one study with DTG (0.3%), none of the studies with BIC, and three of the studies with CAB (0.1-5.4%). In ART-experienced patients, RMs were detected in 0-1.9% of DTG-treated patients. No cases of RM were detected in the 11 BIC studies reviewed. In the case of CAB, RMs were detected in eight studies, ranging from 0.3% to 1.9% of patients. In conclusion, RM rates in the studies reviewed were generally low using the latest INIs. This review identified BIC as the INI with the lowest number of observed VF and lack of RM.

整合酶抑制剂比特拉韦、卡博替拉韦和多罗替拉韦治疗的HIV-1耐药性和病毒学失败:系统性文献综述。
我们描述并分析了使用最新批准的整合酶抑制剂(INIs)多罗特拉韦(DTG)、比特拉韦(BIC)和卡博特拉韦(CAB)及其固定剂量制剂中的配套药物进行抗逆转录病毒治疗的耐药性相关突变(RM)和病毒学失败(VF)情况:BIC/emtricitabine/tenofovir; CAB/rilpivirine; DTG/abacavir/lamivudine; DTG/emtricitabine/tenofovir; 以及 DTG/lamivudine。根据系统综述和荟萃分析指南(PRISMA)的首选报告项目,在PubMed和其他电子数据库中对2010年1月至2023年5月期间发表的临床研究进行了系统文献检索,分析了INIs的VFs和RMs。本综述共纳入了 50 项临床研究。在接受 DTG、BIC 和 CAB 治疗的患者中,抗逆转录病毒治疗(ART)失败患者的 VF 发生率分别为 0.7-4.0%、0.6-1.4% 和 0.6-9.0%。既往接受过抗病毒治疗的患者中,在接受 DTG、BIC 和 CAB 治疗的患者中,分别有 0-8.1%、0-2.0% 和 0.4-2.3% 出现 VF。只有一项使用 DTG 的研究(0.3%)、一项使用 BIC 的研究和三项使用 CAB 的研究(0.1-5.4%)在接受过抗病毒治疗的患者中检测到 RM。在接受过抗病毒治疗的患者中,0-1.9%接受过 DTG 治疗的患者检测到 RM。在审查的 11 项 BIC 研究中未发现 RM 病例。就 CAB 而言,有 8 项研究检测到 RM,占患者的 0.3%-1.9%。总之,使用最新的 INIs 所回顾的研究中,RM 发生率普遍较低。本次回顾发现,BIC 是观察到 VF 和缺乏 RM 的 INI 中数量最少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
AIDS reviews
AIDS reviews 医学-传染病学
CiteScore
3.40
自引率
4.50%
发文量
41
审稿时长
>12 weeks
期刊介绍: AIDS Reviews publishes papers reporting original scientific, clinical, epidemiologic and social research which contribute to the overall knowledge of the field of the acquired immunodeficiency syndrome and human retrovirology. Currently, the Journal publishes review articles (usually by invitation, but spontaneous submitted articles will also be considered). Manuscripts submitted to AIDS Reviews will be accepted on the understanding that the authors have not submitted the paper to another journal or published the material elsewhere.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信